知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.019 seconds)

    Crystalline anti-human IL-23p19 antibodies
    4.
    发明授权
    Crystalline anti-human IL-23p19 antibodies 有权

    公开(公告)号：US09803010B2

    公开(公告)日：2017-10-31

    申请号：US14407319

    申请日：2013-06-25

    Applicant: Merck Sharp & Dohme Corp.

    Inventor： Paul Reichert ,  Winifred W. Prosise ,  Peter Orth ,  Chakravarthy Nachu Narasimhan ,  Ramesh S. Kashi

    IPC: C07K16/24 ,  A61K39/395

    CPC classification number: C07K16/244 ,  A61K39/39591 ,  C07K2299/00 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.

    CRYSTALLINE ANTI-HUMAN IL-23 ANTIBODIES
    8.
    发明申请
    CRYSTALLINE ANTI-HUMAN IL-23 ANTIBODIES 有权
    结晶抗人IL-23抗体

    公开(公告)号：US20150147337A1

    公开(公告)日：2015-05-28

    申请号：US14407319

    申请日：2013-06-25

    Applicant: Merck Sharp & Dohme Corp.

    Inventor： Paul Reichert ,  Winifred W. Prosise ,  Peter Orth ,  Chakravarthy Nachu Narasimhan ,  Ramesh S. Kashi

    IPC: C07K16/24

    CPC classification number: C07K16/244 ,  A61K39/39591 ,  C07K2299/00 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

    Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.

    Abstract translation: 提供了对人IL-23的抗体的结晶形式，例如针对人IL-23p19的抗体，以及产生此类结晶形式的方法，以及使用这种结晶形式，例如， 治疗炎症，自身免疫和增殖性疾病。 在各种实施方案中，本发明的抗hulL-23p19抗体晶体可以通过分批结晶法，蒸气扩散法，液 - 液扩散法和透析法获得。 在其它方面，本发明涉及本发明的结晶抗hLL-23抗体的悬浮液，包括在相同抗体浓度下与相应的非结晶溶液相比可能的浓度更高和粘度更低的那些。 在其它实施方案中，本发明的抗-HLL-23抗体晶体具有提高的稳定性，即它们比抗相对应的溶液制剂更长时间保持抗-HuiL-23抗体（例如抗-HLL-23p19抗体）的生物学活性。

Patent Agency Ranking